These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 24628993)

  • 1. Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer.
    Kanteti R; El-Hashani E; Dhanasingh I; Tretiakova M; Husain AN; Sharma S; Sharma J; Vokes EE; Salgia R
    BMC Cancer; 2014 Mar; 14():185. PubMed ID: 24628993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential expression of RON in small and non-small cell lung cancers.
    Kanteti R; Krishnaswamy S; Catenacci D; Tan YH; EL-Hashani E; Cervantes G; Husain AN; Tretiakova M; Vokes EE; Huet H; Salgia R
    Genes Chromosomes Cancer; 2012 Sep; 51(9):841-51. PubMed ID: 22585712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription.
    Kanteti R; Nallasura V; Loganathan S; Tretiakova M; Kroll T; Krishnaswamy S; Faoro L; Cagle P; Husain AN; Vokes EE; Lang D; Salgia R
    Lab Invest; 2009 Mar; 89(3):301-14. PubMed ID: 19139719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.
    Catenacci DV; Cervantes G; Yala S; Nelson EA; El-Hashani E; Kanteti R; El Dinali M; Hasina R; Brägelmann J; Seiwert T; Sanicola M; Henderson L; Grushko TA; Olopade O; Karrison T; Bang YJ; Kim WH; Tretiakova M; Vokes E; Frank DA; Kindler HL; Huet H; Salgia R
    Cancer Biol Ther; 2011 Jul; 12(1):9-46. PubMed ID: 21543897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.
    Ma PC; Jagadeeswaran R; Jagadeesh S; Tretiakova MS; Nallasura V; Fox EA; Hansen M; Schaefer E; Naoki K; Lader A; Richards W; Sugarbaker D; Husain AN; Christensen JG; Salgia R
    Cancer Res; 2005 Feb; 65(4):1479-88. PubMed ID: 15735036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells.
    Jagadeeswaran R; Jagadeeswaran S; Bindokas VP; Salgia R
    Am J Physiol Lung Cell Mol Physiol; 2007 Jun; 292(6):L1488-94. PubMed ID: 17322284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-overexpression of Met and hepatocyte growth factor promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells.
    Navab R; Liu J; Seiden-Long I; Shih W; Li M; Bandarchi B; Chen Y; Lau D; Zu YF; Cescon D; Zhu CQ; Organ S; Ibrahimov E; Ohanessian D; Tsao MS
    Neoplasia; 2009 Dec; 11(12):1292-300. PubMed ID: 20019837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer.
    Kawada I; Hasina R; Arif Q; Mueller J; Smithberger E; Husain AN; Vokes EE; Salgia R
    Cancer Res; 2014 Feb; 74(3):884-95. PubMed ID: 24305878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative characterization of the HGF/Met and MSP/Ron systems in primary pancreatic adenocarcinoma.
    Vanderwerff BR; Church KJ; Kawas LH; Harding JW
    Cytokine; 2019 Nov; 123():154762. PubMed ID: 31254927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. OPN promotes the aggressiveness of non-small-cell lung cancer cells through the activation of the RON tyrosine kinase.
    Hao C; Cui Y; Chang S; Huang J; Birkin E; Hu M; Zhi X; Li W; Zhang L; Cheng S; Jiang WG
    Sci Rep; 2019 Dec; 9(1):18101. PubMed ID: 31792339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MACC‑1 antibody target therapy suppresses growth and migration of non‑small cell lung cancer.
    Shi W; Song J; Wang W; Zhang Y; Zheng S
    Mol Med Rep; 2017 Nov; 16(5):7329-7336. PubMed ID: 28944826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ETS2 mediated tumor suppressive function and MET oncogene inhibition in human non-small cell lung cancer.
    Kabbout M; Garcia MM; Fujimoto J; Liu DD; Woods D; Chow CW; Mendoza G; Momin AA; James BP; Solis L; Behrens C; Lee JJ; Wistuba II; Kadara H
    Clin Cancer Res; 2013 Jul; 19(13):3383-95. PubMed ID: 23659968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AXL and MET receptor tyrosine kinases are essential for lung cancer metastasis.
    Choi YJ; Kim JH; Rho JK; Kim JS; Choi CM; Kim WS; Son J; Lee JC
    Oncol Rep; 2017 Apr; 37(4):2201-2208. PubMed ID: 28260071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-198 inhibition of HGF/c-MET signaling pathway overcomes resistance to radiotherapy and induces apoptosis in human non-small-cell lung cancer.
    Zhu L; Xue F; Xu X; Xu J; Hu S; Liu S; Cui Y; Gao C
    J Cell Biochem; 2018 Sep; 119(9):7873-7886. PubMed ID: 29943841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential expression of Met/hepatocyte growth factor receptor in subtypes of non-small cell lung cancers.
    Tsao MS; Liu N; Chen JR; Pappas J; Ho J; To C; Viallet J; Park M; Zhu H
    Lung Cancer; 1998 Apr; 20(1):1-16. PubMed ID: 9699182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of the recepteur d'originenantais receptor tyrosine kinase in non-small cell lung cancer and its clinical significance.
    Han WL; Li WD; Hu J; Rusidanmu A; Chen LF; Shen L; Zheng SS
    Chin Med J (Engl); 2012 Mar; 125(6):1110-4. PubMed ID: 22613539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative signaling pathways as potential therapeutic targets for overcoming EGFR and c-Met inhibitor resistance in non-small cell lung cancer.
    Fong JT; Jacobs RJ; Moravec DN; Uppada SB; Botting GM; Nlend M; Puri N
    PLoS One; 2013; 8(11):e78398. PubMed ID: 24223799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. c-Met is a potentially new therapeutic target for treatment of human melanoma.
    Puri N; Ahmed S; Janamanchi V; Tretiakova M; Zumba O; Krausz T; Jagadeeswaran R; Salgia R
    Clin Cancer Res; 2007 Apr; 13(7):2246-53. PubMed ID: 17404109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HGF/c-Met overexpressions, but not met mutation, correlates with progression of non-small cell lung cancer.
    Gumustekin M; Kargi A; Bulut G; Gozukizil A; Ulukus C; Oztop I; Atabey N
    Pathol Oncol Res; 2012 Apr; 18(2):209-18. PubMed ID: 21779788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ERK2 but not ERK1 mediates HGF-induced motility in non-small cell lung carcinoma cell lines.
    Radtke S; Milanovic M; Rossé C; De Rycker M; Lachmann S; Hibbert A; Kermorgant S; Parker PJ
    J Cell Sci; 2013 Jun; 126(Pt 11):2381-91. PubMed ID: 23549785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.